基于噬菌体展示技术的罗非鱼抗无乳链球菌表位疫苗的评价。

IF 3.9 2区 农林科学 Q1 FISHERIES
Jun-Jie Sheng , Xue-Feng Wei , Mao-Lin Liu , Xiao-Hang Ren , Ming-Zhu Liu , Bin Zhu
{"title":"基于噬菌体展示技术的罗非鱼抗无乳链球菌表位疫苗的评价。","authors":"Jun-Jie Sheng ,&nbsp;Xue-Feng Wei ,&nbsp;Mao-Lin Liu ,&nbsp;Xiao-Hang Ren ,&nbsp;Ming-Zhu Liu ,&nbsp;Bin Zhu","doi":"10.1016/j.fsi.2025.110896","DOIUrl":null,"url":null,"abstract":"<div><div>Tilapia ranks among the world's leading aquaculture species, but <em>Streptococcus agalactiae</em> (<em>S. agalactiae</em>) severely limits the growth of the global tilapia industry. Vaccination has been proven to be a promising strategy for controlling this disease. In this study, a Ph.D.-12 phage display library was screened using serum from <em>S. agalactiae</em> survivors, leading to the identification and synthesis of two peptides (P1 and P2). Subsequently, an epitope vaccine was prepared by combining the peptide with adjuvant, and tilapia were immunized with a prime-boost strategy to evaluate its protective effect. Serum and tissue samples of immunized fish were collected periodically after the primary immunization, and the immunization effect was evaluated by combining enzyme-linked immunosorbent assay (ELISA), enzyme activity assays and quantitative real-time PCR (qRT-PCR). The results showed that the vaccine significantly enhanced host immune responses, including elevated specific antibody titers and upregulation of <em>CD8</em>, a marker of T cell activation. Notably, the epitope vaccine conferred protection against <em>S. agalactiae</em> challenge within 14 days post-challenge with a survival rate of up to 54.29 % in the group treated with Adjuvant-P1 (20 μg/g). Unlike traditional reverse vaccinology approaches, this method employed phage display to directly identify conformational epitopes, leading to the discovery of new conserved epitopes and suggesting that P1 and P2 peptide mimotopes hold potential as <em>S. agalactiae</em> candidate antigens. However, while this study provided preliminary evidence of the vaccine's efficacy against <em>S. agalactiae</em> over a 35-day period, further validation of the vaccine's durability and generalizability by extending the observation window and using different <em>S. agalactiae</em> strains is necessary. In conclusion, two mimotopes against <em>S. agalactiae</em> were directly identified by phage display in this study, which lays the foundation for the development of highly efficient and chemically synthesizable <em>S. agalactiae</em> vaccines for tilapia, and contributes to the promotion of the sustainable development of the tilapia industry.</div></div>","PeriodicalId":12127,"journal":{"name":"Fish & shellfish immunology","volume":"167 ","pages":"Article 110896"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of a tilapia epitopes vaccine against Streptococcus agalactiae based on phage display technology\",\"authors\":\"Jun-Jie Sheng ,&nbsp;Xue-Feng Wei ,&nbsp;Mao-Lin Liu ,&nbsp;Xiao-Hang Ren ,&nbsp;Ming-Zhu Liu ,&nbsp;Bin Zhu\",\"doi\":\"10.1016/j.fsi.2025.110896\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Tilapia ranks among the world's leading aquaculture species, but <em>Streptococcus agalactiae</em> (<em>S. agalactiae</em>) severely limits the growth of the global tilapia industry. Vaccination has been proven to be a promising strategy for controlling this disease. In this study, a Ph.D.-12 phage display library was screened using serum from <em>S. agalactiae</em> survivors, leading to the identification and synthesis of two peptides (P1 and P2). Subsequently, an epitope vaccine was prepared by combining the peptide with adjuvant, and tilapia were immunized with a prime-boost strategy to evaluate its protective effect. Serum and tissue samples of immunized fish were collected periodically after the primary immunization, and the immunization effect was evaluated by combining enzyme-linked immunosorbent assay (ELISA), enzyme activity assays and quantitative real-time PCR (qRT-PCR). The results showed that the vaccine significantly enhanced host immune responses, including elevated specific antibody titers and upregulation of <em>CD8</em>, a marker of T cell activation. Notably, the epitope vaccine conferred protection against <em>S. agalactiae</em> challenge within 14 days post-challenge with a survival rate of up to 54.29 % in the group treated with Adjuvant-P1 (20 μg/g). Unlike traditional reverse vaccinology approaches, this method employed phage display to directly identify conformational epitopes, leading to the discovery of new conserved epitopes and suggesting that P1 and P2 peptide mimotopes hold potential as <em>S. agalactiae</em> candidate antigens. However, while this study provided preliminary evidence of the vaccine's efficacy against <em>S. agalactiae</em> over a 35-day period, further validation of the vaccine's durability and generalizability by extending the observation window and using different <em>S. agalactiae</em> strains is necessary. In conclusion, two mimotopes against <em>S. agalactiae</em> were directly identified by phage display in this study, which lays the foundation for the development of highly efficient and chemically synthesizable <em>S. agalactiae</em> vaccines for tilapia, and contributes to the promotion of the sustainable development of the tilapia industry.</div></div>\",\"PeriodicalId\":12127,\"journal\":{\"name\":\"Fish & shellfish immunology\",\"volume\":\"167 \",\"pages\":\"Article 110896\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fish & shellfish immunology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1050464825007855\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"FISHERIES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fish & shellfish immunology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1050464825007855","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"FISHERIES","Score":null,"Total":0}
引用次数: 0

摘要

罗非鱼是世界领先的水产养殖物种之一,但无乳链球菌(S. agalactiae)严重限制了全球罗非鱼产业的发展。疫苗接种已被证明是控制这种疾病的一种有希望的策略。本研究利用无乳链球菌(S. agalactiae)幸存者血清筛选ph . d . 12噬菌体展示文库,鉴定并合成了两个肽(P1和P2)。随后,将该肽与佐剂结合制备抗原表位疫苗,并对罗非鱼进行始发-强化免疫,评价其保护作用。初次免疫后定期采集免疫鱼的血清和组织样本,结合酶联免疫吸附试验(ELISA)、酶活性测定和实时荧光定量PCR (qRT-PCR)评价免疫效果。结果表明,该疫苗显著增强了宿主的免疫应答,包括特异性抗体滴度升高和CD8 (T细胞活化的标志)的上调。值得注意的是,佐剂p1 (20 μg/g)组的表位疫苗在攻击后14天内对无乳链球菌的攻击具有保护作用,存活率高达54.29%。与传统的反向疫苗学方法不同,该方法利用噬菌体展示直接鉴定构象表位,从而发现了新的保守表位,并表明P1和P2肽模位具有作为无乳链球菌候选抗原的潜力。然而,尽管本研究在35天内提供了疫苗对无乳链球菌有效的初步证据,但有必要通过延长观察窗口和使用不同的无乳链球菌菌株来进一步验证疫苗的持久性和普遍性。综上所述,本研究通过噬菌体展示技术直接鉴定出两种抗无乳链球菌的拟合酶,为开发高效、化学可合成的罗非鱼无乳链球菌疫苗奠定基础,有助于促进罗非鱼产业的可持续发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of a tilapia epitopes vaccine against Streptococcus agalactiae based on phage display technology
Tilapia ranks among the world's leading aquaculture species, but Streptococcus agalactiae (S. agalactiae) severely limits the growth of the global tilapia industry. Vaccination has been proven to be a promising strategy for controlling this disease. In this study, a Ph.D.-12 phage display library was screened using serum from S. agalactiae survivors, leading to the identification and synthesis of two peptides (P1 and P2). Subsequently, an epitope vaccine was prepared by combining the peptide with adjuvant, and tilapia were immunized with a prime-boost strategy to evaluate its protective effect. Serum and tissue samples of immunized fish were collected periodically after the primary immunization, and the immunization effect was evaluated by combining enzyme-linked immunosorbent assay (ELISA), enzyme activity assays and quantitative real-time PCR (qRT-PCR). The results showed that the vaccine significantly enhanced host immune responses, including elevated specific antibody titers and upregulation of CD8, a marker of T cell activation. Notably, the epitope vaccine conferred protection against S. agalactiae challenge within 14 days post-challenge with a survival rate of up to 54.29 % in the group treated with Adjuvant-P1 (20 μg/g). Unlike traditional reverse vaccinology approaches, this method employed phage display to directly identify conformational epitopes, leading to the discovery of new conserved epitopes and suggesting that P1 and P2 peptide mimotopes hold potential as S. agalactiae candidate antigens. However, while this study provided preliminary evidence of the vaccine's efficacy against S. agalactiae over a 35-day period, further validation of the vaccine's durability and generalizability by extending the observation window and using different S. agalactiae strains is necessary. In conclusion, two mimotopes against S. agalactiae were directly identified by phage display in this study, which lays the foundation for the development of highly efficient and chemically synthesizable S. agalactiae vaccines for tilapia, and contributes to the promotion of the sustainable development of the tilapia industry.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Fish & shellfish immunology
Fish & shellfish immunology 农林科学-海洋与淡水生物学
CiteScore
7.50
自引率
19.10%
发文量
750
审稿时长
68 days
期刊介绍: Fish and Shellfish Immunology rapidly publishes high-quality, peer-refereed contributions in the expanding fields of fish and shellfish immunology. It presents studies on the basic mechanisms of both the specific and non-specific defense systems, the cells, tissues, and humoral factors involved, their dependence on environmental and intrinsic factors, response to pathogens, response to vaccination, and applied studies on the development of specific vaccines for use in the aquaculture industry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信